APO Research
Talk to an analyst

APO RESEARCH · REPORT

Pleurodynia Treatment

Compare research editions
View pricing & licenses

Selected research

Industry Research

Pleurodynia Treatment Industry Research Report 2026

22 December 2025131 pages

Choose your research edition.

Industry ResearchPleurodynia Treatment Industry Research Report 2026131 pages · $2,950 USDIndustry Growth & TrendsGlobal Pleurodynia Treatment Industry Growth and Trends Forecast to 2032113 pages · $3,450 USDMarket StructureGlobal Pleurodynia Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pleurodynia Treatment Market Outlook and Growth Opportunities 2026202 pages · $4,250 USDMarket Analysis & ForecastGlobal Pleurodynia Treatment Market Analysis and Forecast 2026-2032208 pages · $4,950 USD

Market perspective

The global Pleurodynia Treatment market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Pleurodynia Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Pleurodynia Treatment is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Pleurodynia Treatment is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Pleurodynia Treatment include Takeda Pharmaceuticals, Teva Pharmaceutical lndustries, Sanofi, Johnson & Johnson, Novartis, Merck & Co., Eli Lilly and Company, Pfizer and GlaxoSmithKline, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Pleurodynia Treatment market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Pleurodynia Treatment Market by Company

Takeda Pharmaceuticals

Teva Pharmaceutical lndustries

Sanofi

Johnson & Johnson

Novartis

Merck & Co.

Eli Lilly and Company

Pfizer

GlaxoSmithKline

Bayer

Bristol Myers Squibb

Amgen

AbbVie

AstraZeneca

Roche Holding AG

Gilead Sciences

Daiichi Sankyo

Boehringer Ingelheim

Astellas Pharma.

Pleurodynia Treatment Segment by Type

Anti-Inflammatory Drugs

Analgesics

Other

Pleurodynia Treatment Segment by Application

Hospital

Clinic

Other

Pleurodynia Treatment Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pleurodynia Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pleurodynia Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pleurodynia Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Pleurodynia Treatment manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Pleurodynia Treatment by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Pleurodynia Treatment in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Pleurodynia Treatment Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Pleurodynia Treatment Sales (k units) of Manufacturers (2021-2026) Table 7. Global Pleurodynia Treatment Sales Market Share by Manufacturers (2021-2026) Table 8. Global Pleurodynia Treatment Revenue of Manufacturers (2021-2026) Table 9. Global Pleurodynia Treatment Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Pleurodynia Treatment Average Price (US$/unit) of Manufacturers (2021-2026) Table 11. Global Pleurodynia Treatment Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Pleurodynia Treatment, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Pleurodynia Treatment, Product Type & Application Table 14. Global Pleurodynia Treatment Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Pleurodynia Treatment by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Takeda Pharmaceuticals Company Information Table 19. Takeda Pharmaceuticals Business Overview Table 20. Takeda Pharmaceuticals Pleurodynia Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 21. Takeda Pharmaceuticals Pleurodynia Treatment Product Portfolio Table 22. Takeda Pharmaceuticals Recent Developments Table 23. Teva Pharmaceutical lndustries Company Information Table 24. Teva Pharmaceutical lndustries Business Overview Table 25. Teva Pharmaceutical lndustries Pleurodynia Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 26. Teva Pharmaceutical lndustries Pleurodynia Treatment Product Portfolio Table 27. Teva Pharmaceutical lndustries Recent Developments Table 28. Sanofi Company Information Table 29. Sanofi Business Overview Table 30. Sanofi Pleurodynia Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 31. Sanofi Pleurodynia Treatment Product Portfolio Table 32. Sanofi Recent Developments Table 33. Johnson & Johnson Company Information Table 34. Johnson & Johnson Business Overview Table 35. Johnson & Johnson Pleurodynia Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 36. Johnson & Johnson Pleurodynia Treatment Product Portfolio Table 37. Johnson & Johnson Recent Developments Table 38. Novartis Company Information Table 39. Novartis Business Overview Table 40. Novartis Pleurodynia Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 41. Novartis Pleurodynia Treatment Product Portfolio Table 42. Novartis Recent Developments Table 43. Merck & Co. Company Information Table 44. Merck & Co. Business Overview Table 45. Merck & Co. Pleurodynia Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 46. Merck & Co. Pleurodynia Treatment Product Portfolio Table 47. Merck & Co. Recent Developments Table 48. Eli Lilly and Company Company Information Table 49. Eli Lilly and Company Business Overview Table 50. Eli Lilly and Company Pleurodynia Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 51. Eli Lilly and Company Pleurodynia Treatment Product Portfolio Table 52. Eli Lilly and Company Recent Developments Table 53. Pfizer Company Information Table 54. Pfizer Business Overview Table 55. Pfizer Pleurodynia Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 56. Pfizer Pleurodynia Treatment Product Portfolio Table 57. Pfizer Recent Developments Table 58. GlaxoSmithKline Company Information Table 59. GlaxoSmithKline Business Overview Table 60. GlaxoSmithKline Pleurodynia Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 61. GlaxoSmithKline Pleurodynia Treatment Product Portfolio Table 62. GlaxoSmithKline Recent Developments Table 63. Bayer Company Information Table 64. Bayer Business Overview Table 65. Bayer Pleurodynia Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 66. Bayer Pleurodynia Treatment Product Portfolio Table 67. Bayer Recent Developments Table 68. Bristol Myers Squibb Company Information Table 69. Bristol Myers Squibb Business Overview Table 70. Bristol Myers Squibb Pleurodynia Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 71. Bristol Myers Squibb Pleurodynia Treatment Product Portfolio Table 72. Bristol Myers Squibb Recent Developments Table 73. Amgen Company Information Table 74. Amgen Business Overview Table 75. Amgen Pleurodynia Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. Amgen Pleurodynia Treatment Product Portfolio Table 77. Amgen Recent Developments Table 78. AbbVie Company Information Table 79. AbbVie Business Overview Table 80. AbbVie Pleurodynia Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. AbbVie Pleurodynia Treatment Product Portfolio Table 82. AbbVie Recent Developments Table 83. AstraZeneca Company Information Table 84. AstraZeneca Business Overview Table 85. AstraZeneca Pleurodynia Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. AstraZeneca Pleurodynia Treatment Product Portfolio Table 87. AstraZeneca Recent Developments Table 88. Roche Holding AG Company Information Table 89. Roche Holding AG Business Overview Table 90. Roche Holding AG Pleurodynia Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. Roche Holding AG Pleurodynia Treatment Product Portfolio Table 92. Roche Holding AG Recent Developments Table 93. Gilead Sciences Company Information Table 94. Gilead Sciences Business Overview Table 95. Gilead Sciences Pleurodynia Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 96. Gilead Sciences Pleurodynia Treatment Product Portfolio Table 97. Gilead Sciences Recent Developments Table 98. Daiichi Sankyo Company Information Table 99. Daiichi Sankyo Business Overview Table 100. Daiichi Sankyo Pleurodynia Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 101. Daiichi Sankyo Pleurodynia Treatment Product Portfolio Table 102. Daiichi Sankyo Recent Developments Table 103. Boehringer Ingelheim Company Information Table 104. Boehringer Ingelheim Business Overview Table 105. Boehringer Ingelheim Pleurodynia Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 106. Boehringer Ingelheim Pleurodynia Treatment Product Portfolio Table 107. Boehringer Ingelheim Recent Developments Table 108. Astellas Pharma. Company Information Table 109. Astellas Pharma. Business Overview Table 110. Astellas Pharma. Pleurodynia Treatment Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 111. Astellas Pharma. Pleurodynia Treatment Product Portfolio Table 112. Astellas Pharma. Recent Developments Table 113. Global Pleurodynia Treatment Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 114. Global Pleurodynia Treatment Sales by Region (2021-2026) & (k units) Table 115. Global Pleurodynia Treatment Sales Market Share by Region (2021-2026) Table 116. Global Pleurodynia Treatment Sales by Region (2027-2032) & (k units) Table 117. Global Pleurodynia Treatment Sales Market Share by Region (2027-2032) Table 118. Global Pleurodynia Treatment Revenue by Region (2021-2026) & (US$ Million) Table 119. Global Pleurodynia Treatment Revenue Market Share by Region (2021-2026) Table 120. Global Pleurodynia Treatment Revenue by Region (2027-2032) & (US$ Million) Table 121. Global Pleurodynia Treatment Revenue Market Share by Region (2027-2032) Table 122. North America Pleurodynia Treatment Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 123. North America Pleurodynia Treatment Sales by Country (2021-2026) & (k units) Table 124. North America Pleurodynia Treatment Sales by Country (2027-2032) & (k units) Table 125. North America Pleurodynia Treatment Revenue by Country (2021-2026) & (US$ Million) Table 126. North America Pleurodynia Treatment Revenue by Country (2027-2032) & (US$ Million) Table 127. Europe Pleurodynia Treatment Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 128. Europe Pleurodynia Treatment Sales by Country (2021-2026) & (k units) Table 129. Europe Pleurodynia Treatment Sales by Country (2027-2032) & (k units) Table 130. Europe Pleurodynia Treatment Revenue by Country (2021-2026) & (US$ Million) Table 131. Europe Pleurodynia Treatment Revenue by Country (2027-2032) & (US$ Million) Table 132. Asia Pacific Pleurodynia Treatment Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 133. Asia Pacific Pleurodynia Treatment Sales by Country (2021-2026) & (k units) Table 134. Asia Pacific Pleurodynia Treatment Sales by Country (2027-2032) & (k units) Table 135. Asia Pacific Pleurodynia Treatment Revenue by Country (2021-2026) & (US$ Million) Table 136. Asia Pacific Pleurodynia Treatment Revenue by Country (2027-2032) & (US$ Million) Table 137. South America Pleurodynia Treatment Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 138. South America Pleurodynia Treatment Sales by Country (2021-2026) & (k units) Table 139. South America Pleurodynia Treatment Sales by Country (2027-2032) & (k units) Table 140. South America Pleurodynia Treatment Revenue by Country (2021-2026) & (US$ Million) Table 141. South America Pleurodynia Treatment Revenue by Country (2027-2032) & (US$ Million) Table 142. Middle East and Africa Pleurodynia Treatment Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 143. Middle East and Africa Pleurodynia Treatment Sales by Country (2021-2026) & (k units) Table 144. Middle East and Africa Pleurodynia Treatment Sales by Country (2027-2032) & (k units) Table 145. Middle East and Africa Pleurodynia Treatment Revenue by Country (2021-2026) & (US$ Million) Table 146. Middle East and Africa Pleurodynia Treatment Revenue by Country (2027-2032) & (US$ Million) Table 147. Global Pleurodynia Treatment Sales by Type (2021-2026) & (k units) Table 148. Global Pleurodynia Treatment Sales by Type (2027-2032) & (k units) Table 149. Global Pleurodynia Treatment Sales Market Share by Type (2021-2026) Table 150. Global Pleurodynia Treatment Sales Market Share by Type (2027-2032) Table 151. Global Pleurodynia Treatment Revenue by Type (2021-2026) & (US$ Million) Table 152. Global Pleurodynia Treatment Revenue by Type (2027-2032) & (US$ Million) Table 153. Global Pleurodynia Treatment Revenue Market Share by Type (2021-2026) Table 154. Global Pleurodynia Treatment Revenue Market Share by Type (2027-2032) Table 155. Global Pleurodynia Treatment Price by Type (2021-2026) & (US$/unit) Table 156. Global Pleurodynia Treatment Price by Type (2027-2032) & (US$/unit) Table 157. Global Pleurodynia Treatment Sales by Application (2021-2026) & (k units) Table 158. Global Pleurodynia Treatment Sales by Application (2027-2032) & (k units) Table 159. Global Pleurodynia Treatment Sales Market Share by Application (2021-2026) Table 160. Global Pleurodynia Treatment Sales Market Share by Application (2027-2032) Table 161. Global Pleurodynia Treatment Revenue by Application (2021-2026) & (US$ Million) Table 162. Global Pleurodynia Treatment Revenue by Application (2027-2032) & (US$ Million) Table 163. Global Pleurodynia Treatment Revenue Market Share by Application (2021-2026) Table 164. Global Pleurodynia Treatment Revenue Market Share by Application (2027-2032) Table 165. Global Pleurodynia Treatment Price by Application (2021-2026) & (US$/unit) Table 166. Global Pleurodynia Treatment Price by Application (2027-2032) & (US$/unit) Table 167. Key Raw Materials Table 168. Raw Materials Key Suppliers Table 169. Pleurodynia Treatment Distributors List Table 170. Pleurodynia Treatment Customers List Table 171. Pleurodynia Treatment Industry Trends Table 172. Pleurodynia Treatment Industry Drivers Table 173. Pleurodynia Treatment Industry Restraints Table 174. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Pleurodynia Treatment Product Image Figure 5. Global Pleurodynia Treatment Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Pleurodynia Treatment Market Size (2021-2032) & (US$ Million) Figure 7. Global Pleurodynia Treatment Sales (2021-2032) & (k units) Figure 8. Global Pleurodynia Treatment Average Price (US$/unit) & (2021-2032) Figure 9. Anti-Inflammatory Drugs Product Image Figure 10. Analgesics Product Image Figure 11. Other Product Image Figure 12. Hospital Product Image Figure 13. Clinic Product Image Figure 14. Other Product Image Figure 15. Global Pleurodynia Treatment Revenue Share by Manufacturers in 2025 Figure 16. Global Manufacturers of Pleurodynia Treatment, Manufacturing Sites & Headquarters Figure 17. Global Top 5 and 10 Pleurodynia Treatment Players Market Share by Revenue in 2025 Figure 18. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Pleurodynia Treatment Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 20. Global Pleurodynia Treatment Sales by Region in 2025 Figure 21. Global Pleurodynia Treatment Revenue by Region in 2025 Figure 22. North America Pleurodynia Treatment Market Size by Country in 2025 Figure 23. North America Pleurodynia Treatment Sales Market Share by Country (2021-2032) Figure 24. North America Pleurodynia Treatment Revenue Market Share by Country (2021-2032) Figure 25. United States Pleurodynia Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 26. Canada Pleurodynia Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Mexico Pleurodynia Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Europe Pleurodynia Treatment Market Size by Country in 2025 Figure 29. Europe Pleurodynia Treatment Sales Market Share by Country (2021-2032) Figure 30. Europe Pleurodynia Treatment Revenue Market Share by Country (2021-2032) Figure 31. Germany Pleurodynia Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. France Pleurodynia Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. U.K. Pleurodynia Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Italy Pleurodynia Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Russia Pleurodynia Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Spain Pleurodynia Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Netherlands Pleurodynia Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Switzerland Pleurodynia Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Sweden Pleurodynia Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Poland Pleurodynia Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Asia Pacific Pleurodynia Treatment Market Size by Country in 2025 Figure 42. Asia Pacific Pleurodynia Treatment Sales Market Share by Country (2021-2032) Figure 43. Asia Pacific Pleurodynia Treatment Revenue Market Share by Country (2021-2032) Figure 44. China Pleurodynia Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. Japan Pleurodynia Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. South Korea Pleurodynia Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. India Pleurodynia Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Australia Pleurodynia Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Taiwan Pleurodynia Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Southeast Asia Pleurodynia Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Southeast Asia Pleurodynia Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. South America Pleurodynia Treatment Market Size by Country in 2025 Figure 53. South America Pleurodynia Treatment Sales Market Share by Country (2021-2032) Figure 54. South America Pleurodynia Treatment Revenue Market Share by Country (2021-2032) Figure 55. Brazil Pleurodynia Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Argentina Pleurodynia Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Chile Pleurodynia Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Middle East and Africa Pleurodynia Treatment Market Size by Country in 2025 Figure 59. Middle East and Africa Pleurodynia Treatment Sales Market Share by Country (2021-2032) Figure 60. Middle East and Africa Pleurodynia Treatment Revenue Market Share by Country (2021-2032) Figure 61. Egypt Pleurodynia Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. South Africa Pleurodynia Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. Israel Pleurodynia Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. Türkiye Pleurodynia Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. GCC Countries Pleurodynia Treatment Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. Global Pleurodynia Treatment Sales Market Share by Type (2021-2032) Figure 67. Global Pleurodynia Treatment Revenue Market Share by Type (2021-2032) Figure 68. Global Pleurodynia Treatment Price (US$/unit) by Type (2021-2032) Figure 69. Global Pleurodynia Treatment Sales Market Share by Application (2021-2032) Figure 70. Global Pleurodynia Treatment Revenue Market Share by Application (2021-2032) Figure 71. Global Pleurodynia Treatment Price (US$/unit) by Application (2021-2032) Figure 72. Pleurodynia Treatment Value Chain Figure 73. Pleurodynia Treatment Production Mode & Process Figure 74. Direct Comparison with Distribution Share Figure 75. Distributors Profiles Figure 76. Pleurodynia Treatment Industry Opportunities and Challenges

Scope & coverage.

Types
  • Anti-Inflammatory Drugs
  • Analgesics
  • Other
Applications
  • Hospital
  • Clinic
  • Other
Companies covered
  • Takeda Pharmaceuticals
  • Teva Pharmaceutical lndustries
  • Sanofi
  • Johnson & Johnson
  • Novartis
  • Merck & Co.
  • Eli Lilly and Company
  • Pfizer
  • GlaxoSmithKline
  • Bayer
  • Bristol Myers Squibb
  • Amgen
  • AbbVie
  • AstraZeneca
  • Roche Holding AG
  • Gilead Sciences
  • Daiichi Sankyo
  • Boehringer Ingelheim
  • Astellas Pharma.

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Pleurodynia Treatment Market Size (2021-2032)
  4. 2.2.2 Global Pleurodynia Treatment Sales (2021-2032)
  5. 2.2.3 Global Pleurodynia Treatment Market Average Price (2021-2032)
  6. 2.3 Pleurodynia Treatment by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Anti-Inflammatory Drugs
  9. 2.3.3 Analgesics
  10. 2.3.4 Other
  11. 2.4 Pleurodynia Treatment by Application
  12. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  13. 2.4.2 Hospital
  14. 2.4.3 Clinic
  15. 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Pleurodynia Treatment Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Pleurodynia Treatment Sales (k units) of Manufacturers (2021-2026)
  3. 3.3 Global Pleurodynia Treatment Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Pleurodynia Treatment Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Pleurodynia Treatment Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Pleurodynia Treatment, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Pleurodynia Treatment, Product Type & Application
  8. 3.8 Global Manufacturers of Pleurodynia Treatment, Established Date
  9. 3.9 Global Pleurodynia Treatment Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Takeda Pharmaceuticals
  2. 4.1.1 Takeda Pharmaceuticals Company Information
  3. 4.1.2 Takeda Pharmaceuticals Business Overview
  4. 4.1.3 Takeda Pharmaceuticals Pleurodynia Treatment Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Takeda Pharmaceuticals Pleurodynia Treatment Product Portfolio
  6. 4.1.5 Takeda Pharmaceuticals Recent Developments
  7. 4.2 Teva Pharmaceutical lndustries
  8. 4.2.1 Teva Pharmaceutical lndustries Company Information
  9. 4.2.2 Teva Pharmaceutical lndustries Business Overview
  10. 4.2.3 Teva Pharmaceutical lndustries Pleurodynia Treatment Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Teva Pharmaceutical lndustries Pleurodynia Treatment Product Portfolio
  12. 4.2.5 Teva Pharmaceutical lndustries Recent Developments
  13. 4.3 Sanofi
  14. 4.3.1 Sanofi Company Information
  15. 4.3.2 Sanofi Business Overview
  16. 4.3.3 Sanofi Pleurodynia Treatment Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Sanofi Pleurodynia Treatment Product Portfolio
  18. 4.3.5 Sanofi Recent Developments
  19. 4.4 Johnson & Johnson
  20. 4.4.1 Johnson & Johnson Company Information
  21. 4.4.2 Johnson & Johnson Business Overview
  22. 4.4.3 Johnson & Johnson Pleurodynia Treatment Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Johnson & Johnson Pleurodynia Treatment Product Portfolio
  24. 4.4.5 Johnson & Johnson Recent Developments
  25. 4.5 Novartis
  26. 4.5.1 Novartis Company Information
  27. 4.5.2 Novartis Business Overview
  28. 4.5.3 Novartis Pleurodynia Treatment Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Novartis Pleurodynia Treatment Product Portfolio
  30. 4.5.5 Novartis Recent Developments
  31. 4.6 Merck & Co.
  32. 4.6.1 Merck & Co. Company Information
  33. 4.6.2 Merck & Co. Business Overview
  34. 4.6.3 Merck & Co. Pleurodynia Treatment Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Merck & Co. Pleurodynia Treatment Product Portfolio
  36. 4.6.5 Merck & Co. Recent Developments
  37. 4.7 Eli Lilly and Company
  38. 4.7.1 Eli Lilly and Company Company Information
  39. 4.7.2 Eli Lilly and Company Business Overview
  40. 4.7.3 Eli Lilly and Company Pleurodynia Treatment Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Eli Lilly and Company Pleurodynia Treatment Product Portfolio
  42. 4.7.5 Eli Lilly and Company Recent Developments
  43. 4.8 Pfizer
  44. 4.8.1 Pfizer Company Information
  45. 4.8.2 Pfizer Business Overview
  46. 4.8.3 Pfizer Pleurodynia Treatment Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Pfizer Pleurodynia Treatment Product Portfolio
  48. 4.8.5 Pfizer Recent Developments
  49. 4.9 GlaxoSmithKline
  50. 4.9.1 GlaxoSmithKline Company Information
  51. 4.9.2 GlaxoSmithKline Business Overview
  52. 4.9.3 GlaxoSmithKline Pleurodynia Treatment Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 GlaxoSmithKline Pleurodynia Treatment Product Portfolio
  54. 4.9.5 GlaxoSmithKline Recent Developments
  55. 4.10 Bayer
  56. 4.10.1 Bayer Company Information
  57. 4.10.2 Bayer Business Overview
  58. 4.10.3 Bayer Pleurodynia Treatment Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Bayer Pleurodynia Treatment Product Portfolio
  60. 4.10.5 Bayer Recent Developments
  61. 4.11 Bristol Myers Squibb
  62. 4.11.1 Bristol Myers Squibb Company Information
  63. 4.11.2 Bristol Myers Squibb Business Overview
  64. 4.11.3 Bristol Myers Squibb Pleurodynia Treatment Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Bristol Myers Squibb Pleurodynia Treatment Product Portfolio
  66. 4.11.5 Bristol Myers Squibb Recent Developments
  67. 4.12 Amgen
  68. 4.12.1 Amgen Company Information
  69. 4.12.2 Amgen Business Overview
  70. 4.12.3 Amgen Pleurodynia Treatment Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Amgen Pleurodynia Treatment Product Portfolio
  72. 4.12.5 Amgen Recent Developments
  73. 4.13 AbbVie
  74. 4.13.1 AbbVie Company Information
  75. 4.13.2 AbbVie Business Overview
  76. 4.13.3 AbbVie Pleurodynia Treatment Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 AbbVie Pleurodynia Treatment Product Portfolio
  78. 4.13.5 AbbVie Recent Developments
  79. 4.14 AstraZeneca
  80. 4.14.1 AstraZeneca Company Information
  81. 4.14.2 AstraZeneca Business Overview
  82. 4.14.3 AstraZeneca Pleurodynia Treatment Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 AstraZeneca Pleurodynia Treatment Product Portfolio
  84. 4.14.5 AstraZeneca Recent Developments
  85. 4.15 Roche Holding AG
  86. 4.15.1 Roche Holding AG Company Information
  87. 4.15.2 Roche Holding AG Business Overview
  88. 4.15.3 Roche Holding AG Pleurodynia Treatment Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Roche Holding AG Pleurodynia Treatment Product Portfolio
  90. 4.15.5 Roche Holding AG Recent Developments
  91. 4.16 Gilead Sciences
  92. 4.16.1 Gilead Sciences Company Information
  93. 4.16.2 Gilead Sciences Business Overview
  94. 4.16.3 Gilead Sciences Pleurodynia Treatment Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Gilead Sciences Pleurodynia Treatment Product Portfolio
  96. 4.16.5 Gilead Sciences Recent Developments
  97. 4.17 Daiichi Sankyo
  98. 4.17.1 Daiichi Sankyo Company Information
  99. 4.17.2 Daiichi Sankyo Business Overview
  100. 4.17.3 Daiichi Sankyo Pleurodynia Treatment Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 Daiichi Sankyo Pleurodynia Treatment Product Portfolio
  102. 4.17.5 Daiichi Sankyo Recent Developments
  103. 4.18 Boehringer Ingelheim
  104. 4.18.1 Boehringer Ingelheim Company Information
  105. 4.18.2 Boehringer Ingelheim Business Overview
  106. 4.18.3 Boehringer Ingelheim Pleurodynia Treatment Sales, Revenue and Gross Margin (2021-2026)
  107. 4.18.4 Boehringer Ingelheim Pleurodynia Treatment Product Portfolio
  108. 4.18.5 Boehringer Ingelheim Recent Developments
  109. 4.19 Astellas Pharma.
  110. 4.19.1 Astellas Pharma. Company Information
  111. 4.19.2 Astellas Pharma. Business Overview
  112. 4.19.3 Astellas Pharma. Pleurodynia Treatment Sales, Revenue and Gross Margin (2021-2026)
  113. 4.19.4 Astellas Pharma. Pleurodynia Treatment Product Portfolio
  114. 4.19.5 Astellas Pharma. Recent Developments
5 Global Pleurodynia Treatment Market Scenario by Region
  1. 5.1 Global Pleurodynia Treatment Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Pleurodynia Treatment Sales by Region: 2021-2032
  3. 5.2.1 Global Pleurodynia Treatment Sales by Region: 2021-2026
  4. 5.2.2 Global Pleurodynia Treatment Sales by Region: 2027-2032
  5. 5.3 Global Pleurodynia Treatment Revenue by Region: 2021-2032
  6. 5.3.1 Global Pleurodynia Treatment Revenue by Region: 2021-2026
  7. 5.3.2 Global Pleurodynia Treatment Revenue by Region: 2027-2032
  8. 5.4 North America Pleurodynia Treatment Market Facts & Figures by Country
  9. 5.4.1 North America Pleurodynia Treatment Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Pleurodynia Treatment Sales by Country (2021-2032)
  11. 5.4.3 North America Pleurodynia Treatment Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Pleurodynia Treatment Market Facts & Figures by Country
  16. 5.5.1 Europe Pleurodynia Treatment Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Pleurodynia Treatment Sales by Country (2021-2032)
  18. 5.5.3 Europe Pleurodynia Treatment Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Pleurodynia Treatment Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Pleurodynia Treatment Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Pleurodynia Treatment Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Pleurodynia Treatment Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Pleurodynia Treatment Market Facts & Figures by Country
  41. 5.7.1 South America Pleurodynia Treatment Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Pleurodynia Treatment Sales by Country (2021-2032)
  43. 5.7.3 South America Pleurodynia Treatment Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Pleurodynia Treatment Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Pleurodynia Treatment Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Pleurodynia Treatment Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Pleurodynia Treatment Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Pleurodynia Treatment Sales by Type (2021-2032)
  2. 6.1.1 Global Pleurodynia Treatment Sales by Type (2021-2032) & (k units)
  3. 6.1.2 Global Pleurodynia Treatment Sales Market Share by Type (2021-2032)
  4. 6.2 Global Pleurodynia Treatment Revenue by Type (2021-2032)
  5. 6.2.1 Global Pleurodynia Treatment Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Pleurodynia Treatment Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Pleurodynia Treatment Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Pleurodynia Treatment Sales by Application (2021-2032)
  2. 7.1.1 Global Pleurodynia Treatment Sales by Application (2021-2032) & (k units)
  3. 7.1.2 Global Pleurodynia Treatment Sales Market Share by Application (2021-2032)
  4. 7.2 Global Pleurodynia Treatment Revenue by Application (2021-2032)
  5. 7.2.1 Global Pleurodynia Treatment Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Pleurodynia Treatment Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Pleurodynia Treatment Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Pleurodynia Treatment Value Chain Analysis
  2. 8.1.1 Pleurodynia Treatment Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Pleurodynia Treatment Production Mode & Process
  5. 8.2 Pleurodynia Treatment Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Pleurodynia Treatment Distributors
  8. 8.2.3 Pleurodynia Treatment Customers
9 Global Pleurodynia Treatment Analyzing Market Dynamics
  1. 9.1 Pleurodynia Treatment Industry Trends
  2. 9.2 Pleurodynia Treatment Industry Drivers
  3. 9.3 Pleurodynia Treatment Industry Opportunities and Challenges
  4. 9.4 Pleurodynia Treatment Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst